Human placental leucine aminopeptidase (P-LAP) as a hypotensive agent

1982 ◽  
Vol 38 (7) ◽  
pp. 821-822 ◽  
Author(s):  
S. Mizutani ◽  
K. Okano ◽  
E. Hasegawa ◽  
H. Sakura ◽  
M. Oya ◽  
...  
Keyword(s):  
Leucine Aminopeptidase ◽  
Hypotensive Agent ◽  
Aminopeptidase P

Construction of a novel asymmetric imidazole-cored AIE probe for ratiometric imaging of endogenous leucine aminopeptidase

2021 ◽  
Author(s):  
Xueyan Huang ◽  
Qian Lei ◽  
Shuai Huang ◽  
Hongliang Zeng ◽  
Bin Feng ◽  
...  
Keyword(s):  
Leucine Aminopeptidase ◽  
Aminopeptidase P ◽  
Ratiometric Imaging

We reported a rational strategy to deliberately construct the first asymmetric tetraarylimidazole-based AIE probe, integrating AIE behavior in synergy with ESIPT character to ratiometric imaging of endogenous LAP for the...

Plasma angiotensin I and serum placental leucine aminopeptidase (P-LAP) in pre-eclampsia

1985 ◽  
Vol 236 (3) ◽  
pp. 165-172 ◽  
Author(s):  
S. Mizutani ◽  
H. Akiyama ◽  
O. Kurauchi ◽  
H. Taira ◽  
O. Narita ◽  
...  
Keyword(s):  
Leucine Aminopeptidase ◽  
Angiotensin I ◽  
Plasma Angiotensin ◽  
Aminopeptidase P

Simultaneous determinations of plasma oxytocin and serum placental leucine aminopeptidase (P-LAP) during late pregnancy

1982 ◽  
Vol 15 (3) ◽  
pp. 141-145 ◽  
Author(s):  
Shigehiko Mizutani ◽  
Hide Hayakawa ◽  
Haruyuki Akiyama ◽  
Harutake Sakura ◽  
Masataka Yoshino ◽  
...  
Keyword(s):  
Leucine Aminopeptidase ◽  
Late Pregnancy ◽  
Aminopeptidase P

scholarly journals A novel role for placental leucine aminopeptidase (P-LAP) as a determinant of chemoresistance in endometrial carcinoma cells

2005 ◽  
Vol 118 (6) ◽  
pp. 1390-1394 ◽  
Author(s):  
Chihiro Kondo ◽  
Kiyosumi Shibata ◽  
Mikio Terauchi ◽  
Hiroaki Kajiyama ◽  
Kazuhiko Ino ◽  
...  
Keyword(s):  
Endometrial Carcinoma ◽  
Leucine Aminopeptidase ◽  
Carcinoma Cells ◽  
Aminopeptidase P

Relationship Between the Changes in Maternal Serum Placental Leucine Aminopeptidase (P-LAP) Activity and Umbilical Artery Waveforms in Normal Pregnancy

1996 ◽  
Vol 28 (03) ◽  
pp. 147-149 ◽  
Author(s):  
S. Mohamed ◽  
S. Mizutani ◽  
A. Itakura ◽  
N. Kuno ◽  
H. Salem ◽  
...  
Keyword(s):  
Umbilical Artery ◽  
Leucine Aminopeptidase ◽  
Normal Pregnancy ◽  
Maternal Serum ◽  
Aminopeptidase P

Oxytocinase: Placental Cystine Aminopeptidase or Placental Leucine Aminopeptidase (P-LAP)

1992 ◽  
Vol 10 (02) ◽  
pp. 146-153 ◽  
Author(s):  
Shigehiko Mizutani ◽  
Yutaka Tomoda
Keyword(s):  
Leucine Aminopeptidase ◽  
Aminopeptidase P

scholarly journals Placental Leucine Aminopeptidase as a Potential Specific Urine Biomarker for Invasive Ovarian Cancer

2021 ◽  
Vol 11 (1) ◽  
pp. 222
Author(s):  
Tetsuya Matsukawa ◽  
Shigehiko Mizutani ◽  
Kunio Matsumoto ◽  
Yukio Kato ◽  
Masato Yoshihara ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Sensitivity And Specificity ◽  
Malignant Tumor ◽  
Leucine Aminopeptidase ◽  
Invasive Cancer ◽  
Non Invasive ◽  
Tumor Group ◽  
Urine Biomarker ◽  
The Mean ◽  
Aminopeptidase P

Background: A non-invasive and sensitive biomarker for the detection of ovarian cancer (OvCa) is lacking. We aim to investigate if urinary placental leucine aminopeptidase (P-LAP) can serve as a reliable biomarker for OvCa. Methods: P-LAP activity was measured using a LAP assay kit (Serotech Co., Ltd., Sapporo, Japan) in the urine of 22 patients with benign or borderline malignant ovarian tumors and 18 patients with OvCa. In this assay, L-methionine was added at 20 mM because P-LAP is functional, but other aminopeptidases are inhibited at this dose of L-methionine. Results: The mean urinary P-LAP activity was significantly higher in the OvCa group than in the benign or borderline malignant tumor group. When the cut-off value of P-LAP was determined as 11.00 U/L, its sensitivity and specificity for differentiating invasive cancer were 77.8% and 95.5%, respectively. Conclusion: Although the usefulness of this test should be confirmed in a larger cohort of cases and controls, our study is the first to highlight the importance of urinary P-LAP as a biomarker for OvCa.

In vitro degradation of angiotensin II (A-II) by human placental subcellular fractions, pregnancy sera and purified placental aminopeptidases

1985 ◽  
Vol 110 (1) ◽  
pp. 135-139 ◽  
Author(s):  
Shigehiko Mizutani ◽  
Haruyuki Akiyama ◽  
Osamu Kurauchi ◽  
Hiroyuki Taira ◽  
Osamu Narita ◽  
...  
Keyword(s):  
Amino Acids ◽  
Angiotensin Ii ◽  
High Performance ◽  
Leucine Aminopeptidase ◽  
Soluble Fraction ◽  
In Vitro Degradation ◽  
Aminopeptidase A ◽  
Aminopeptidase P ◽  
Soluble Fractions

Abstract. The degradation of angiotensin II (Asp1-Arg2-Val3-Tyr4-Ile5-His6-Pro7-Phe8: A-II) by human placental particulate and soluble fractions, pregnant and non-pregnant sera, and highly purified placental enzymes such as placental leucine aminopeptidase P-LAP (microsomal), retroplacental serum P-LAP (soluble), aminopeptidase A and post-proline endopeptidase, was studied by measuring liberated amino acids by high performance liquid chromatography. Placental particulate and soluble fractions degraded A-II almost completely into single amino acids. The purified P-LAP (microsomal) actively liberated five amino acids from the N-terminal. The placental particulate fraction containing P-LAP (microsomal) also actively liberated these amino acids. The purified aminopeptidase A liberated Asp1 very actively as expected. When the ratio of the velocity of liberation of each amino acid to P-LAP activity measured with leu-p-nitroanilide as a substrate was calculated, placental soluble fraction liberated Asp1 very actively, but the liberation rate of Asp1 with the purified P-LAP (soluble) was very low. Therefore it seems that the enzyme in the placental soluble fraction and pregnancy serum responsible for the Asp1 liberation is not P-LAP (soluble), but aminopeptidase A. The mixture of purified P-LAP (soluble) and aminopeptidase A showed higher liberation rate of Arg2 and Val3 than that with purified aminopeptidase A alone, demonstrating that once the N-terminal Asp1 was liberated, the P-LAP (soluble) attacks the shorter peptide (angiotension III) very actively. It was concluded that P-LAP (microsomal) together with aminopeptidase A seem to contribute greatly to the degradation of A-II in pregnant women.

Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia

2005 ◽  
Vol 98 (1) ◽  
pp. 11-18 ◽  
Author(s):  
Kiyosumi Shibata ◽  
Hiroaki Kajiyama ◽  
Yayoi Mizokami ◽  
Kazuhiko Ino ◽  
Seiji Nomura ◽  
...  
Keyword(s):  
Glucose Transporter ◽  
Leucine Aminopeptidase ◽  
Glucose Transporter 4 ◽  
Glut4 Expression ◽  
Aminopeptidase P
Sign in / Sign up

Export Citation Format

Share Document